Emergent BioSolutions (EBS) director reports option exercise and stock sales

Rhea-AI Filing Summary

Emergent BioSolutions director reported multiple stock transactions in the company’s shares. On December 5, 2025, the director exercised 25,748 stock options at an exercise price of $5.02 per share, receiving the same number of common shares. To cover the option exercise price and applicable taxes, 10,864 shares were sold, with additional open‑market sales of 7,100 shares at a weighted average price of $12.1113 and 14,884 shares at a weighted average price of $11.8978. After these transactions, the director held 98,417 shares of common stock directly and no remaining derivative securities from this option grant.

Insider Trade Summary

Net Seller: 21,984 shares ($263,077)

Net Sell 5 txns

Insider Richard Ronald

Role Director

Sold 21,984 shs ($263K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	25,748	$0.00	--
Sale	Common Stock	7,100	$12.1113	$86K
Exercise	Common Stock	25,748	$5.02	$129K
Tax Withholding	Common Stock	10,864	$11.8978	$129K
Sale	Common Stock	14,884	$11.8978	$177K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 98,417 shares (Direct)

Footnotes (1)

1. Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12. Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Richard Ronald

(Last) (First) (Middle)

300 PROFESSIONAL DR

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	12/05/2025	12/05/2025	S		7,100	D	$12.1113(2)	98,417	D
Common Stock	12/05/2025	12/05/2025	M		25,748	A	$5.02	124,165	D
Common Stock	12/05/2025	12/05/2025	F		10,864(3)	D	$11.8978(4)	113,301	D
Common Stock	12/05/2025	12/05/2025	S		14,884	D	$11.8978(4)	98,417	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.02	12/05/2025	12/05/2025	M			25,748	(5)	05/22/2031	Common Stock	25,748	$0	0	D

Explanation of Responses:

1. Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.

2. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12.

3. Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise.

4. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97.

5. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did the EBS director report?

The director reported exercising 25,748 stock options for Emergent BioSolutions common stock and selling portions of the resulting shares on December 5, 2025.

How many Emergent BioSolutions (EBS) shares did the director sell?

The director sold 7,100 shares at a weighted average price of $12.1113 and later 14,884 shares at a weighted average price of $11.8978, plus shares to cover the option exercise and taxes.

What was the exercise price of the Emergent BioSolutions stock options?

The stock options were exercised at an exercise price of $5.02 per share for 25,748 shares of Emergent BioSolutions common stock.

How many EBS shares does the director own after these transactions?

Following the reported transactions, the director directly beneficially owns 98,417 shares of Emergent BioSolutions common stock.

Why were some Emergent BioSolutions shares sold immediately after the option exercise?

The filing states that 10,864 shares were sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise.

What do the weighted average sale prices for EBS shares represent?

The weighted average prices of $12.1113 and $11.8978 reflect multiple transactions in price ranges of $12.11–$12.12 and $11.88–$11.97, respectively.